The subject of the contract is the supply of the manufactured investigational medicinal product for the University

Medical Research in Łódź as part of the project: "Randomized, double-blind, placebo-controlled study evaluating the effectiveness and safety of dimethyl fumarate in reducing brain atrophy, improving

synaptic functional connections, cognition, functioning, and quality of life in patients with

diagnosis of mild cognitive impairment and dementia in Alzheimer's disease."

A detailed description of the object of the contract is Annex 2 to the SWZ.

The Contractor is obliged to perform the contract on the terms and conditions described in the model contract

constituting Annex 4 to the SWZ.

The subject of the contract is the supply of the manufactured investigational medicinal product for the University

Medical University of Lodz as part of the project: "Randomized, double-blind, placebo-controlled

Study evaluating the efficacy and safety of dimethyl fumarate in reducing brain atrophy, improving

synaptic functional connections, cognition, functioning, and quality of life in patients with

diagnosis of mild cognitive impairment and dementia in Alzheimer's disease."

The Contractor will successively (on partial order of the Ordering Party) deliver the tested products

medicinal after repackaging from the following quantities:

1. Medicinal product containing the active substance dimethylfumarate: 901 packs (1 pack of

contain 56 capsules), i.e. a total of 50,456 gastro-resistant capsules (240 mg dimethyl fumarate each) with a period of

validity of not less than 12 months from the date of delivery of the product.

2. placebo (for dimethyl fumarate): 451 packages (1 package should contain 56 capsules), i.e. a total of 25,256

gastro-resistant capsules with a shelf life of not less than 12 months from the date of delivery of the product.